Filing Details

Accession Number:
0001203311-23-000123
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-13 20:02:01
Reporting Period:
2023-11-10
Accepted Time:
2023-11-13 20:02:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1060736 Seagen Inc. SGEN Biological Products, (No Disgnostic Substances) (2836) 911874389
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1445826 R David Epstein 21823 30Th Drive Se
Bothell WA 98021
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-11-10 10,620 $213.01 136,598 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a written agreement governing the terms of restricted stock units granted to the reporting person, which includes a plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) to satisfy tax obligations arising out of the vesting of such stock units (the "Sell-to-Cover Trading Arrangement"). The written agreement, adopted December 14, 2022, provides that, if the filer is in possession of material, nonpublic information as of the date of grant of such stock units, then the Sell-to-Cover Trading Arrangement becomes a binding contract as of the first date thereafter on which the filer is not in possession of material, nonpublic information.
  2. Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.